Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While DSIP was originally described for inducing spindle and delta sleep activity when infused into the brain of rabbits; later studies report stress-modulating and endocrine effects, though its physiological role is still debated47, Retatrutide is an investigational agent that produces very large body-weight reductions in early trials by simultaneously engaging GLP-1R, GIPR, and GCGR to enhance satiety, energy expenditure, and glycemic control2575.
While DSIP works as an endogenous nonapeptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, with proposed neuromodulatory actions; it interacts with components of the MAPK cascade and may be related to glucocorticoid-induced leucine zipper (GILZ), but its precise biosynthetic origin remains unknown4757, Retatrutide is a triple incretin agonist peptide derived from a GIP backbone and engineered to activate GLP-1, GIP, and glucagon receptors, with non-natural residues and fatty-acid conjugation that confer long half-life and balanced multi-receptor signaling256575.
DSIP
Not assigned in the current dataset.
Retatrutide
Not assigned in the current dataset.
DSIP and Retatrutide are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: DSIP is more often discussed in the realm of Neurology and brain health, whereas Retatrutide is more often associated with the realm of Metabolic and endocrine. Their biological logic is quite different: DSIP is a neurotransmitter modulator, whereas Retatrutide is a receptor agonist and a hormone analog. DSIP has a more natural endogenous origin, while Retatrutide is closer to synthetic analog background with DSIP approved for Research use only and Retatrutide in Clinical phase 3. DSIP takes the form of a linear peptide, whereas Retatrutide is closer to a peptide conjugate, while Retatrutide incorporates lipidation features that are not part of DSIP.